ReviewThe Analyst2026
Micro and nanoscale probes for spatiotemporal cell analysis and manipulation.
Review in The Analyst, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding dynamic cellular processes requires technologies capable of probing living cells with high spatial and temporal precision while preserving viability. Conventional approaches, including bulk omics, microinjection, and electroporation, often provide only static snapshots or induce significant cellular perturbation. Recent advances in micro- and nanoscale probes are enabling minimally invasive intracellular delivery, sampling, sensing, and manipulation with unprecedented precision. This review examines the current state of the art in micro and nanoscale probe technologies, including fluidic force microscopy (FluidFM), nanopipettes, open-space microfluidic probes, and nanoneedle arrays. We discuss how these complementary platforms enable controlled delivery of biomolecules, longitudinal molecular sampling, intracellular electrophysiology, electrochemical sensing, and spatiotemporally resolved analyses from single cells to living tissues. We placed particular emphasis on their ability to overcome the limitations of destructive endpoint assays by facilitating repeated interrogation of the same cell, quantitative molecular delivery, and multimodal measurements with subcellular resolution. Finally, we discuss the remaining engineering challenges, including improving throughput, integrating complementary sensing modalities, and advancing these promising technologies into robust platforms for laboratory studies of cultured cells and tissues.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.